scholarly journals A comprehensive individual patient data meta‐analysis of the effects of cardiac contractility modulation on functional capacity and heart failure‐related quality of life

2020 ◽  
Vol 7 (5) ◽  
pp. 2922-2932 ◽  
Author(s):  
Francesco Giallauria ◽  
Gianluigi Cuomo ◽  
Alessandro Parlato ◽  
Nirav Y. Raval ◽  
Jürgen Kuschyk ◽  
...  

2017 ◽  
Vol 52 ◽  
pp. 91-104 ◽  
Author(s):  
Laurien M. Buffart ◽  
Joeri Kalter ◽  
Maike G. Sweegers ◽  
Kerry S. Courneya ◽  
Robert U. Newton ◽  
...  


2020 ◽  
Author(s):  
Mulubirhan Tirfe ◽  
Alemseged Beyene ◽  
Haileselassie Berhane ◽  
Ephrem Engidawork ◽  
Tewolde Teklu

Abstract Background: Heart failure (HF) is associated with severe complications, hospitalization, and poor quality of life. Patients with heart failure had poor physical and emotional symptoms, functional status and worse health outcomes.Objective: The aim of this systematic review and meta-analysis will be to investigate whether pharmacist intervention is effective in improving health related quality of life (HRQoL) and clinical outcomes among patients with heart failure.Method: Systematic review and meta-analysis will be conducted. Published journals in English and indexed in Medline (PubMed), Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and Google scholar will be searched from 1990 to December 2019. Data will be extracted by one author and will be approved by other two authors independently. Data will be analyzed in accordance with the Cochrane handbook. Standardized mean differences will be used as an estimate of the effect size. Quality of included studies will be assessed using the modified Downs and Black checklist. Analysis for the dichotomous outcome studies will be converted into standardized mean difference and present with 95% confidence intervals. The review is approved in the International Prospective Register of Systematic Reviews (PROSPERO) with registration ID CRD42020158236.Discussion: Currently there are important gaps on the effectiveness of pharmacist intervention in improving health-related quality of life and clinical outcomes. We believe this review will provide comprehensive evidence on the effectiveness of pharmacist intervention among patients with HF.



Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 900
Author(s):  
Diana C. Sanchez-Ramirez ◽  
Kaylene Normand ◽  
Yang Zhaoyun ◽  
Rodrigo Torres-Castro

Background: The long-term impact of COVID-19 is still unknown. This study aimed to explore post COVID-19 effects on patients chest computed tomography (CT), lung function, respiratory symptoms, fatigue, functional capacity, health-related quality of life (HRQoL), and the ability to return to work beyond 3 months post infection. Methods: A systematic search was performed on PubMed, Web of Science, and Ovid MEDLINE on 22 May 2021, to identify studies that reported persistent effects of COVID-19 beyond 3 months follow-up. Data on the proportion of patients who had the outcome were collected and analyzed using a one-group meta-analysis. Results: Data were extracted from 24 articles that presented information on a total of 5323 adults, post-infection, between 3 to 6 months after symptom onset or hospital discharge. The pooled prevalence of CT abnormalities was 59% (95% CI 44–73, I2 = 96%), abnormal lung function was 39% (95% CI 24–55, I2 = 94%), fatigue was 38% (95% CI 27–49, I2 = 98%), dyspnea was 32% (95% CI 24–40, I2 = 98%), chest paint/tightness was 16% (95% CI 12–21, I2 = 94%), and cough was 13%, (95% CI 9–17, I2 = 94%). Decreased functional capacity and HRQoL were found in 36% (95% CI 22–49, I2 = 97%) and 52% (95% CI 33–71, I2 = 94%), respectively. On average, 8 out of 10 of the patients had returned to work or reported no work impairment. Conclusion: Post-COVID-19 patients may experience persistent respiratory symptoms, fatigue, decreased functional capacity and decreased quality of life up to 6 months after infection. Further studies are needed to establish the extent to which post-COVID-19 effects continue beyond 6 months, how they interact with each other, and to clarify their causes and their effective management.



2004 ◽  
Vol 10 (5) ◽  
pp. 368-373 ◽  
Author(s):  
Frederick A. Masoudi ◽  
John S. Rumsfeld ◽  
Edward P. Havranek ◽  
John A. House ◽  
Eric D. Peterson ◽  
...  


2021 ◽  
Vol 14 ◽  
pp. 117863292110216
Author(s):  
Ana Helena Cavalheiro ◽  
José Silva Cardoso ◽  
Afonso Rocha ◽  
Emília Moreira ◽  
Luís Filipe Azevedo

Background: Tele-rehabilitation (TR) may be an effective alternative or complement to centre-based cardiac rehabilitation (CBCR) with heart failure (HF) patients, helping overcome accessibility problems to CBCR. The aim of this study is to systematically review the literature in order to assess the clinical effectiveness of TR programs in the management of chronic HF patients, compared to standard of care and standard rehabilitation (CBCR). Methods and Results: We conducted a systematic review and meta-analysis of randomized controlled trials on the effect and safety of TR programs in HF patients, regarding cardiovascular death, heart failure-related hospitalizations, functional capacity and quality of life. We searched 4 electronic databases up until May 2020, reviewed references of relevant articles and contacted experts. A quantitative synthesis of evidence was performed by means of random-effects meta-analyses. We included 17 primary studies, comprising 2206 patients. Four studies reported the number of hospitalizations (TR: 301; Control: 347). TR showed to be effective in the improvement of HF patients’ functional capacity in the 6 Minute Walk-Test (Mean Difference (MD) 15.86; CI 95% [7.23; 24.49]; I2 = 74%) and in peak oxygen uptake (pVO2) results (MD 1.85; CI 95% [0.16; 3.53]; I2 = 93%). It also improved patients’ quality of life (Minnesota Living with Heart Failure Questionnaire: MD −6.62; CI 95% [−11.40; −1.84]; I2 = 99%). No major adverse events were reported during TR exercise. Conclusion: TR showed to be superior than UC without CR on functional capacity improvement in HF patients. There is still scarce evidence of TR impact on hospitalization and cv death reduction. Further research and more standardized protocols are needed to improve evidence on TR effectiveness, safety and cost-effectiveness.



2018 ◽  
Vol 27 (4) ◽  
pp. 1150-1161 ◽  
Author(s):  
J. Kalter ◽  
I.M. Verdonck-de Leeuw ◽  
M.G. Sweegers ◽  
N.K. Aaronson ◽  
P.B. Jacobsen ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document